Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: A systematic review and meta-analysis of real-world data

Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: A systematic review and meta-analysis of real-world data

Breast cancer is a leading cause of cancer-related mortality worldwide, and neoadjuvant chemotherapy (NAC) plays a pivotal role in its management by reducing tumor size, enabling breast-conserving surgery, and improving survival outcomes. Achieving pathologic complete response (pCR) is strongly asso...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcelo Antonini, André Mattar, Thais Melo Pereira, Ludmila Lemos Oliveira, Marina Diógenes Teixeira, Andressa Gonçalves Amorim, Odair Ferraro, Larissa Chrispim de Oliveira, Marcellus do Nascimento Moreira Ramos, Francisco Pimentel Cavalcante, Felipe Zerwes, Marcelo Madeira, Leonardo Ribeiro Soares, Eduardo Camargo Millen, Antonio Luiz Frasson, Fabricio Palermo Brenelli, Gil Facina, Rogerio Fenile, Renata Arakelian, Ruffo de Freitas Júnior, Marcela Bonalumi dos Santos, Henrique Lima Couto, Luiz Henrique Gebrim
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Heliyon
Subjects:
Neoadjuvant chemotherapy
Pathologic complete response
Breast cancer
Survival
Disease-free survival
HER2-Positive
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844025014501
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is a leading cause of cancer-related mortality worldwide, and neoadjuvant chemotherapy (NAC) plays a pivotal role in its management by reducing tumor size, enabling breast-conserving surgery, and improving survival outcomes. Achieving pathologic complete response (pCR) is strongly associated with better overall survival (OS) and disease-free survival (DFS), particularly in aggressive subtypes such as triple-negative (TNBC) and HER2-positive breast cancers. This systematic review and meta-analysis evaluated the correlation between pCR, OS, and DFS in breast cancer patients treated with NAC, focusing exclusively on real-world data (RWD). A comprehensive search with PRISMA guidelines of major databases from 1999 to 2024 identified 22 retrospective studies comprising 12,115 patients. Hazard ratios (HRs) and confidence intervals (CIs) were pooled using random-effects models, and heterogeneity was assessed using the I2 statistic. pCR was achieved in 20.9 % of patients, with higher rates in HER2-positive (44.4 %) and TNBC (31.3 %) subtypes. Achieving pCR was associated with a 30 % improvement in OS (HR: 1.30; 95 % CI: 1.28–1.33) and a 29 % improvement in DFS (HR: 1.29; 95 % CI: 1.24–1.32). Among TNBC patients, pCR correlated with a 51 % increase in DFS (HR: 1.51; 95 % CI: 1.19–1.93). Significant heterogeneity (I2 = 96 %) was observed across studies. These findings highlight the importance of pCR as a robust predictor of improved survival outcomes in breast cancer, particularly in TNBC and HER2-positive subtypes, and underscore the need for strategies to increase pCR rates to enhance long-term survival and disease control.
ISSN:2405-8440

Similar Items